{"filings":[{"id":1111439,"accession_number":"0001104659-26-075151","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-06-17T20:15:28+00:00","items":["5.07"],"status":"ready","headline":"Aprea shareholders approve reverse stock split (1:3–1:8); all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class I director nominees (Duey, Peters, Seizinger) elected; each received >5.4M votes for.","Reverse stock split ratio between 1:3 and 1:8 approved (8.0M for, 210K against); board may effect at its discretion.","Ratification of EisnerAmper as independent auditor for FY2026 passed with 8.1M votes for.","Non-binding say-on-pay passed; advisory vote on frequency favored every 1 year (4.3M votes).","Adjournment proposal also approved with 8.1M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49722,"accession_number":"0001104659-26-059734","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-05-13T10:35:21+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Q1 net loss $3.3M ($0.22/sh); cash $46.5M; APR-1051 shows two partial responses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $46.5M as of Mar 31, 2026, up from $14.6M year-end 2025; runway into Q1 2028.","Operating loss $3.4M for Q1 2026 vs $4.1M in Q1 2025; R&D expense fell to $1.6M from $2.5M.","WEE1 inhibitor APR-1051: two partial responses observed; dose escalation ongoing; ASCO 2026 presentation on May 30.","Oversubscribed $30M private placement closed Mar 31, 2026, led by Soleus Capital to expand APR-1051 enrollment.","ATRN-119 (ATR inhibitor) monotherapy paused; evaluating combination approaches including with radiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95387,"accession_number":"0001104659-26-038258","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aprea Therapeutics closes oversubscribed $30M private placement to fund APR-1051 development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed oversubscribed $30M private placement on March 31, 2026; proceeds for R&D and general corporate.","Proceeds to accelerate APR-1051 development, targeting uterine serous carcinoma and platinum-resistant ovarian cancer with 50+ patients.","Offering led by Soleus Capital; included pre-funded warrants at ~$0.807/sh and warrants at $0.683/sh, expiring Dec 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108445,"accession_number":"0001104659-26-036821","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics raises $30M, confirms partial response for APR-1051 in Phase 1 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$30M via pre-funded warrants ($0.808) and common warrants ($0.683) expiring Dec. 31, 2029; led by Soleus Capital.","Confirmed partial response in PPP2R1A-mutated endometrial cancer patient at 220 mg; target lesion reduction 59.5%, CA-125 drop from 362 to 40.2 U/mL.","Two partial responses in endometrial cancer with PPP2R1A mutations; five stable diseases including HPV+ HNSCC, colorectal, and endometrial cancers.","Cash runway extended into Q1 2028; dose escalation to 300 mg QD planned in Q2 2026.","Oversubscribed offering; Oppenheimer & Co. and Maxim Group acted as placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108444,"accession_number":"0001104659-26-028046","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics reports FY2025 net loss of $12.6M; APR-1051 shows two partial responses","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $14.6M at Dec 31, 2025; plus Jan 2026 private placement of $5.6M funds operations into Q1 2027.","Net loss $12.6M ($1.93/share) for FY2025 vs $13.0M ($2.35/share) in FY2024; R&D spend down to $7.0M from $9.4M.","APR-1051 (WEE1 inhibitor) yields two unconfirmed partial responses in PPP2R1A-mutated endometrial cancer; dose escalation ongoing at 220 mg.","ATRN-119 (ATR inhibitor) RP2D set at 1,100 mg; monotherapy enrollment paused, exploring combination studies.","Appointed Eugene Kennedy, MD, as Chief Medical Advisor in February 2026 to support next phase of development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108443,"accession_number":"0001104659-26-016797","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea reports second partial response for APR-1051; endometrial cancer with PPP2R1A mutation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second unconfirmed partial response (uPR) at 220 mg dose: 50% tumor shrinkage (RECIST v1.1) and CA-125 drop from 362 to 47 U/mL (-87%).","Both uPRs observed in endometrial cancer patients with PPP2R1A mutations; both remain on therapy with only Grade 1 adverse events.","Total 22 patients dosed (10–220 mg); five stable disease across four tumor types including HPV-positive HNSCC and FBXW7-mutated colon cancer.","First uPR previously reported at 150 mg; data support genomically guided WEE1 inhibition with favorable tolerability to date.","Next data update expected Q2 2026; enrollment continues at 220 mg and expansion in PPP2R1A endometrial and HPV-positive HNSCC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108442,"accession_number":"0001104659-26-007988","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Aprea reports first partial response for APR-1051; raises $5.6M in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First unconfirmed partial response (uPR) in PPP2R1A-mutated endometrial cancer at 150 mg: 50% target lesion reduction, CA-125 from 732 to 70 U/mL.","Stable disease at 70 mg (HNSCC, 5% reduction) and 100 mg (colon cancer, 15% reduction; >210 days on therapy).","Private placement ~$5.6M gross: 6.3M shares/pre-funded warrants + 6.3M warrants at $0.765; priced $0.89/unit. Closes Jan 30, 2026.","Dose escalation continues; 220 mg cohort enrolling; company plans to increase HPV-positive enrollment.","Potential dose-response trend observed across 70 mg, 100 mg, and 150 mg cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108441,"accession_number":"0001104659-26-006267","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aprea Therapeutics receives Nasdaq bid price deficiency notice; stock at risk of delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid below $1.00 for 30 consecutive business days triggered Nasdaq deficiency letter.","Company has 180 calendar days (until July 22, 2026) to regain compliance via $1.00 close for 10 consecutive days.","If not cured by July 22, Aprea may qualify for a second 180-day period if it meets other listing standards.","Company may consider a reverse stock split to cure the deficiency but no assurance of compliance.","Stock continues trading on Nasdaq Capital Market under symbol APRE with no immediate delisting effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108440,"accession_number":"0001104659-26-002490","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics updates corporate presentation (January 2026)","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated corporate presentation as Exhibit 99.1 on January 9, 2026.","No specific financial or operational details disclosed in the filing itself.","Presentation content not provided; unable to extract material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124881,"accession_number":"0001104659-25-119680","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Aprea Therapeutics raises $3.1M in private placement priced at $1.165/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$3.1M from 2.62M shares (or pre-funded warrants) and warrants at $1.04 exercise price.","Combined effective price $1.165 per unit; warrants exercisable for 5 years.","Net proceeds to extend cash runway into Q1 2027; closing expected December 10, 2025.","Maxim Group LLC sole placement agent; receives 7% fee and 257,510 placement agent warrants.","Includes participation from new and existing healthcare investors and insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124880,"accession_number":"0001104659-25-109860","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics Q3 net loss $3.0M; cash runway into Q4 2026; clinical updates on APR-1051 and ATRN-119","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $13.7M as of Sep 30, 2025; operating loss $3.1M vs $4.1M YoY.","Net loss $3.0M ($0.47 per basic share) on 6.4M weighted avg shares; R&D expenses $1.6M.","APR-1051 Phase 1: 3 of 4 patients at 100mg QD achieved stable disease; dose escalation advanced to 150mg.","ATRN-119: RP2D set at 1,100mg QD; enrollment paused to explore combination studies with radiation.","Cash sufficient into Q4 2026; anticipates value-creating catalysts in 2026."],"consensus_eps_estimate":-0.3453,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124879,"accession_number":"0001104659-25-102004","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea reports 3 of 4 patients with stable disease at 100 mg APR-1051 in Phase 1 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3 of 4 heavily pretreated patients achieved stable disease (RECIST v1.1) at 100 mg dose level.","Disease stabilization observed in tumors with FBXW7, CCNE1, KRAS G12V, TP53 mutations.","No dose-limiting toxicities reported; dose escalation continues at 150 mg cohort.","Poster presented at AACR-NCI-EORTC conference on Oct 24, 2025; data cutoff Sep 17, 2025.","Individual responses: rectal cancer patient on 145 days of treatment with -13% reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124878,"accession_number":"0001104659-25-099534","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea sets ATRN-119 RP2D at 1,100 mg QD; pauses monotherapy; prioritizes WEE1 inhibitor APR-1051","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RP2D of 1,100 mg once daily identified for ATRN-119 from ABOYA-119 Phase 1/2a study.","Further enrollment paused in both QD and BID monotherapy arms; currently-dosed patients continue without interruption.","Considering combination with radiation (HPV+ head & neck), ADCs, and checkpoint inhibitors; discussions with academic centers.","Lead WEE1 inhibitor APR-1051 advancing; Phase 1 data expected at AACR-NCI-EORTC conference on Oct 24, 2025.","ATRN-119 showed durable disease stabilization, manageable AEs, dose-proportional PK at RP2D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141585,"accession_number":"0001558370-25-011909","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics files updated corporate slide deck; no material new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated corporate presentation dated September 2025 under Item 8.01.","Presentation titled 'Precision Oncology Through Synthetic Lethality' continues DDR inhibition focus.","No specific financial, clinical, or pipeline milestones were evident from the excerpt provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141584,"accession_number":"0001558370-25-011149","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics Q2 net loss $0.53/sh; cash $16.5M; clinical activity in APR-1051 and ATRN-119","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $16.5M as of June 30, 2025, down from $22.8M at Dec 31, 2024; runway into Q2 2026.","Q2 2025 operating loss $3.4M vs $3.8M in Q2 2024; net loss $3.2M ($0.53 per share) vs $3.5M ($0.58 per share).","Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051: 3 patients with stable disease at 70mg/100mg; dose escalation to 150mg planned.","Phase 1/2a ABOYA-119 trial of ATRN-119: 7 patients stable disease, 3 with tumor shrinkage (7%-21%) at 550mg BID; now dosing 400mg BID.","Additional safety/efficacy data expected H2 2025; RP2D for ATRN-119 and dose-escalation completion for APR-1051 expected H1 2026."],"consensus_eps_estimate":-0.7599,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159432,"accession_number":"0001104659-25-057807","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aprea Therapeutics stockholders elect director slate, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class III directors (Jean-Pierre Bizzari, Oren Gilad, John B. Henneman III) elected with >95% of votes cast for.","Ratification of EisnerAmper LLP as 2025 auditor passed with 2,916,782 for, 49,535 against, 35,669 abstain.","Non-binding advisory vote on exec compensation approved (1,628,716 for, 58,828 against, 34,829 abstain).","Say-on-frequency vote: 1 year received 1,159,068 votes; plurality for 1-year frequency.","Quorum achieved with 3,817,718 shares (69% of shares entitled to vote) represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159431,"accession_number":"0001558370-25-007665","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Q1 net loss $3.9M ($0.66/sh); ATRN-119 shows tumor shrinkage in 3 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $19.3M as of March 31, 2025, sufficient into early Q2 2026.","Operating loss $4.1M (Q1 2025) vs $3.1M (Q1 2024); R&D spending up $0.9M on APR-1051 and ATRN-119 trials.","ATRN-119 ABOYA-119 trial: 3 patients at 550mg BID had tumor shrinkage of 7%, 14%, and 21% below RP2D.","APR-1051 ACESOT-1051 trial enrolling at 100mg QD; next cohort 150mg; preliminary efficacy data expected H2 2025.","Entered Material Transfer Agreement with MD Anderson to study APR-1051 in head and neck cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177826,"accession_number":"0001558370-25-003587","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics reports FY2024 net loss $13M, cash $22.8M; APR-1051 data H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.9M (Q4) and $13.0M (FY2024); cash $22.8M, sufficient into Q1 2026.","ACESOT-1051 trial of WEE1 inhibitor APR-1051 enrolling Cohort 5 (70 mg); open-label data expected H2 2025.","ABOYA-119 trial of ATR inhibitor ATRN-119 evaluating BID dosing at Dose Level 7; dose escalation completion H2 2025.","Employment agreement amended for officer John P. Hamill: severance extended to 12 months (18 months post-change-of-control).","R&D expense increased to $9.4M for FY2024 from $7.6M, driven by trial costs and personnel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177825,"accession_number":"0001558370-25-000641","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics updates patent portfolio for ATR and WEE1 inhibitor programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATR inhibitor program: 4 granted US patents, 1 pending US application, 1 provisional; 19 granted non-US patents, 16 pending non-US applications.","Granted patents expire 2035-2037; pending applications may extend exclusivity to 2044.","Lead ATR inhibitor ATRN-119 in Phase 1 ABOYA-119 trial for solid tumors with DDR mutations.","WEE1 inhibitor program: 1 pending US application, 12 pending non-US applications; if granted, expire 2043.","Lead WEE1 inhibitor APR-1051 in Phase 1 ACESOT-1051 trial for advanced/metastatic solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177824,"accession_number":"0001558370-25-000155","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics reports Dec 31, 2024 cash balance of $22.8M","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Cash and cash equivalents of $22.8M as of December 31, 2024 (preliminary, unaudited).","Disclosed via corporate presentation posted to company website on January 13, 2025.","Balance subject to completion of fiscal 2024 year-end financial statements.","No other financial results or guidance provided in the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194532,"accession_number":"0001104659-24-115911","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aprea Therapeutics enters ATM equity offering agreement for up to $3.0M with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aprea entered into an at-the-market offering agreement with H.C. Wainwright to sell up to $3.0M of common stock.","HCW will serve as sales agent and receive a 3.0% commission on gross proceeds from sales.","Net proceeds will fund general corporate purposes, including preclinical studies and clinical trials.","The company is not obligated to sell any shares under the agreement; sales may occur from time to time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194531,"accession_number":"0001558370-24-014768","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics Reports Q3 2024 Financial Results; Cash $26.2M, Net Loss $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents of $26.2 million as of Sept 30, 2024, providing at least twelve months of runway.","Operating loss of $4.1 million for Q3 2024 versus $3.5 million in Q3 2023; net loss of $3.8 million ($0.64 per share).","Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 shows well-tolerated profile with no unexpected toxicities at subtherapeutic doses.","Phase 1/2a ABOYA-119 trial of ATR inhibitor ATRN-119 enrolling at dose level 6 (800 mg QD); twice-daily dosing added to protocol.","Engaged Philippe Pultar, MD as senior medical advisor in October 2024 to support APR-1051 development."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194530,"accession_number":"0001558370-24-013486","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aprea reports preliminary Phase 1 safety data for WEE1 inhibitor APR-1051; no hematologic toxicity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["APR-1051 safe and well-tolerated in first three patients; all adverse events Grade 1-2, no neutropenia or QT prolongation.","Phase 1 ACESOT-1051 study evaluating 10–150 mg daily doses; 8 cohorts planned, subtherapeutic doses given in cohorts 1-3.","Data cutoff Oct 7, 2024: one patient progressed at 49 days, one withdrew at 36 days, third continues on treatment.","Active enrollment at 3 U.S. sites (NEXT Oncology in San Antonio & Dallas, MD Anderson); preliminary efficacy data expected in 2025.","APR-1051 designed for selective WEE1 inhibition without PLK off-target effects seen with other WEE1 inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194529,"accession_number":"0001104659-24-107219","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea reports preliminary cash of $26.2M; CMO Mirza steps down, engages Dr. Pultar as advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Preliminary cash and equivalents ~$26.2M as of Sep 30, 2024, down from $28.7M at Jun 30, 2024.","Dr. Nadeem Mirza steps down as CMO effective Oct 9, 2024; will remain through Dec 13, 2024.","Engaged Dr. Philippe Pultar as Senior Medical Advisor to lead WEE1 inhibitor APR-1051 Phase 1 trial.","Patient enrollment ongoing in Phase 1 ACESOT-1051 study for APR-1051; update expected by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210863,"accession_number":"0001558370-24-011808","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics reports Q2 2024 net loss of $3.5M; Phase 1 trial initiated for APR-1051","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $28.7M as of June 30, 2024, up from $21.6M at Dec 31, 2023; runway extended into Q4 2025.","Net loss $3.5M ($0.58 per share) vs $3.3M ($0.87) in Q2 2023; operating loss $3.8M.","Enrollment commenced in Phase 1 ACESOT-1051 trial of APR-1051 (WEE1 inhibitor); no myelosuppression in first cohort.","ABOYA-119 Phase 1/2a trial of ATRN-119 (ATR inhibitor) continues; first five dose cohorts completed; Phase 1 readout expected 1H 2025.","Appointed Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer effective May 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229275,"accession_number":"0001104659-24-073396","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aprea Therapeutics stockholders elect three Class II directors, ratify EisnerAmper as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 70.46% represented at June 20, 2024 annual meeting.","Michael Grissinger, Gabriela Gruia, Rifat Pamukcu elected as Class II directors with >3M votes each vs. ~55K withheld.","Ratification of EisnerAmper LLP as auditor approved: 3,788,888 for, 7,750 against, 29,541 abstain.","Broker non-votes of 719,524 on director elections; none on ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229274,"accession_number":"0001558370-24-009225","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics doses first patient in Phase 1 trial of oral WEE1 inhibitor APR-1051","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in ACESOT-1051 Phase 1 trial of oral WEE1 inhibitor APR-1051 as monotherapy in advanced solid tumors.","APR-1051 is a potent, highly selective WEE1 inhibitor designed to limit off-target PLK inhibition and improve PK profile.","Trial targets tumors with CCNE1/2 amplification, FBXW7/PPP2R1A mutations, KRAS-G12/TP53 co-mutated CRC, or uterine serous carcinoma.","Dose escalation (up to 39 patients) and dose optimization (up to 40 patients) to determine RP2D; first site at NEXT Oncology (San Antonio).","Company expects clinical update by year-end 2024 and preliminary efficacy data in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229273,"accession_number":"0001558370-24-008070","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics Q1 net loss $2.8M; cash $32.4M; APR-1051 IND cleared; Phase 1 starts June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.8M ($0.67 per share) vs $4.4M ($1.34) in prior year; operating loss $3.1M down from $4.6M.","Cash and equivalents $32.4M as of March 31, 2024, up from $21.6M at Dec 31, 2023; runway into Q3 2025.","FDA cleared IND for APR-1051 (WEE1 inhibitor) in March 2024; Phase 1 ACESOT-1051 trial expected to start June 2024.","Phase 1/2a ATRN-119 (ATR inhibitor) trial continues; dose escalation completion expected 4Q 2024; initial efficacy data possible 2H 2024.","Completed $16M upfront private placement in March 2024 with potential for additional $18M warrants; appointed Nadeem Mirza as CMO effective May 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229272,"accession_number":"0001558370-24-004927","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics clears IND for APR-1051; updates on ATRN-119 Phase 1 at AACR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IND for next-gen WEE1 inhibitor APR-1051 cleared; first patient dosing expected June 2024 in Phase 1 ACESOT-1051 trial.","ATRN-119 (ATR inhibitor) Phase 1/2a: enrolling 550 mg cohort; no DLTs, no Grade 4+ AEs; stable disease in two patients (one on treatment 188+ days).","Preclinical data show APR-1051 has >50-fold reduced PLK off-target inhibition vs ZN-c3; well tolerated with minimal hematotoxicity in mice.","New preclinical ATRN-333 combination with lomustine for glioblastoma shows synergy; intracranial delivery via convection-enhanced device."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247864,"accession_number":"0001558370-24-003887","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics reports FY2023 net loss $14.3M ($3.95/share); cash $21.6M; IND cleared for APR-1051","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $21.6M at Dec 31, 2023; combined with $16M Mar 2024 private placement funds into Q3 2025.","Net loss FY2023 $14.3M ($3.95/basic share) vs $112.7M in FY2022 which included $76M acquired IPR&D charge.","ATRN-119 Phase 1/2a dose escalation on track for 4Q 2024 completion; initial efficacy data expected H2 2024.","FDA cleared IND for APR-1051 (WEE1 inhibitor); Phase 1 ACESOT-1051 trial to start H1 2024.","Operating loss $15.5M in FY2023 vs $113.4M in FY2022; R&D expenses fell to $7.6M from $16.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247863,"accession_number":"0001104659-24-033494","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["1.01","1.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Aprea raises up to $34M in private placement; FDA clears IND for APR-1051","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$16M upfront gross proceeds from private placement; up to $18M additional from warrant exercise.","Financing led by Sphera Healthcare with Nantahala, DAFNA, Exome, Stonepine, and insiders.","Shares at $7.29; Tranche A warrants at $7.29 and Tranche B at $9.1125, tied to RP2D milestones.","FDA cleared IND for APR-1051, a next-gen WEE1 inhibitor for Cyclin E overexpressing cancers.","Phase 1 ACESOT-1051 trial to start H1 2024; update expected Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247862,"accession_number":"0001558370-24-000818","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate presentation slide deck on February 6, 2024.","No specific financial results, clinical data, or strategic changes in the filing.","Presentation likely includes general company overview and pipeline summary.","No guidance, milestones, or forward-looking updates provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247861,"accession_number":"0001104659-24-010057","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Aprea Therapeutics reports preliminary cash balance of $21.6M as of Dec 31, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents, and restricted cash expected to be approximately $21.6 million as of December 31, 2023.","Estimate is unaudited, preliminary, and subject to change upon completion of the year-end financial close process.","Company has not yet completed its financial closing procedures; independent auditor has not reviewed the estimate.","President and CEO Oren Gilad signed the filing; no further financial results or guidance provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247860,"accession_number":"0001104659-24-006976","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aprea Therapeutics enters $1.0M at-the-market equity distribution agreement with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters ATM agreement to sell up to $1.0M of common stock through H.C. Wainwright as agent.","Commission of 3.0% of gross proceeds; net proceeds for general corporate purposes including trials.","Company not obligated to sell any shares; offering made under Form S-3 filed Jan 26, 2024.","At-the-market offering allows stock sales at prevailing market prices over time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247859,"accession_number":"0001558370-24-000060","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics provides 2024 pipeline update: ATRN-119 dose escalation ongoing, IND for APR-1051 expected Q1 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2a trial of ATRN-119 continues; two patients achieved stable disease at 50 mg and 200 mg doses.","Dose-limiting toxicity period for 350 mg cohort completed; RP2D expected H2 2024.","IND submission for next-gen WEE1 inhibitor APR-1051 being finalized; FDA clearance expected Q1 2024.","Preclinical data for APR-1051 show improved selectivity and reduced off-target effects vs other WEE1 inhibitors.","Company to hold investor meetings at LifeSci Partners Corporate Access Event on Jan 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265289,"accession_number":"0001558370-23-018581","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea reports Q3 net loss $3.2M; cash $25.4M; ATRN-1051 IND on track for Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.2M ($0.86/sh) vs $4.0M ($2.32/sh) in Q3 2022; operating loss reduced to $3.5M.","Cash and equivalents $25.4M as of Sep 30, 2023; cash runway through Q4 2024.","ATRN-119 dose escalation at cohort 4 (350mg); dose expansion enrollment expected Q2 2024.","ATRN-1051 IND submission planned Q4 2023 with clearance Q1 2024; Phase 1/2a start H1 2024.","R&D expenses $2.1M (up from $1.1M) due to ATRN-1051 IND studies; G&A down to $1.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265288,"accession_number":"0001558370-23-016468","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea reports Phase 1 safety data for ATRN-119; no hematologic or liver toxicities; WEE1i ATRN-1051 IND planned Q4 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATRN-119 Phase 1/2a dose escalation shows no hematologic or liver toxicities across first three cohorts (50, 100, 200 mg) in heavily pretreated solid tumor patients.","One stable disease observed at 50 mg low dose; dose expansion cohort on track for Q2 2024; currently enrolling 350 mg cohort.","Pre-clinical data for WEE1i ATRN-1051 shows high selectivity for WEE1 and low off-target activity against PLK kinases; IND submission planned for Q4 2023.","ATRN-1051 preclinical findings also show limited effects on red blood cell counts, hERG inhibition, and body weight loss compared to other WEE1 inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265287,"accession_number":"0001558370-23-016426","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics updates corporate presentation slide deck; no specific changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed corporate presentation slide deck dated October 2023; title indicates focus on precision oncology and synthetic lethality.","No quantitative updates (e.g., financial results, clinical data) disclosed in the filing or the provided exhibit excerpt.","Given the absence of specific changes, materiality of this update appears low."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282505,"accession_number":"0001558370-23-015621","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics updates corporate presentation for Sep 2023; details not disclosed in excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing consists solely of an updated corporate slide deck dated September 2023.","Presentation title indicates focus on precision oncology and synthetic lethality.","No financial results, guidance, leadership changes, or deal announcements in the filing.","Exhibit excerpt does not contain specific trial data or operational milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282504,"accession_number":"0001558370-23-015237","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Aprea Therapeutics Board Chair Christian Schade resigns; Richard Peters named Chair, Jean-Pierre Bizzari appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christian S. Schade resigned as director and Board Chair on Aug 23, 2023; no disagreement with company.","Richard Peters, M.D., Ph.D. appointed Board Chair effective immediately after Schade's resignation.","Dr. Jean-Pierre Bizzari appointed as Class III director through 2025 annual meeting; previously at Celgene and Sanofi.","Annual meeting: Class I directors Duey, Peters, Seizinger elected (~1.55M for); auditor EisnerAmper LLP ratified (2.05M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282503,"accession_number":"0001558370-23-014403","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics Q2 net loss $3.3M; cash $27.7M; ATRN-119 data Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.3M ($0.87/sh) vs $98.3M loss in Q2 2022, driven by absence of $76M IPR&D charge from Atrin deal.","Cash and equivalents $27.7M; management expects runway into Q4 2024.","R&D expenses down to $2.2M from $6.8M; G&A down to $1.7M from $15.6M YoY.","ATRN-119 Phase 1/2a enrollment ongoing; initial safety and PK data expected Q4 2023.","Gabriela Gruia, M.D., appointed to Board of Directors; over 25 years clinical and regulatory experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282502,"accession_number":"0001104659-23-078072","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aprea Therapeutics approved to transfer stock listing from Nasdaq Global Select to Capital Market on July 6","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq approval on July 3, 2023 to transfer listing from Global Select to Capital Market.","Transfer becomes effective at the opening of business on July 6, 2023.","Aprea's common stock (APRE) will continue trading on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301732,"accession_number":"0001558370-23-009864","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics Q1 net loss $4.4M; cash runway into Q3 2024; ATRN-119 Phase 1 data expected Q1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.4M ($1.34 per share) on $31.0M cash; operating loss $4.6M vs $8.1M YoY.","R&D expenses $1.3M (down from $4.1M YoY) due to legacy trial closeout; G&A $3.4M.","ATRN-119 Phase 1/2a enrollment continues; initial safety, tolerability, PK data expected Q1 2024.","ATRN-1051 IND-enabling studies ongoing; IND filing anticipated by end of 2023.","Closed $4.9M net proceeds from February public offering; appointed Dr. Gabriela Gruia to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301731,"accession_number":"0001558370-23-008389","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics appoints Gabriela Gruia, M.D. to board; grants 12,500-share option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 8 to 9 directors; Dr. Gruia appointed as Class II director effective May 5, 2023.","Option to purchase 12,500 shares at $3.86 (closing price on grant date) fully vesting in one year.","Dr. Gruia brings 25+ years in oncology drug development; former SVP at Novartis Oncology leading 12 NME approvals.","No familial or transaction relationships requiring disclosure; serves until 2024 annual meeting or resignation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301730,"accession_number":"0001104659-23-046719","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-04-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Aprea Therapeutics dismisses EY, appoints EisnerAmper as new independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On April 17, 2023, Aprea dismissed Ernst & Young LLP as its independent auditor, effective immediately.","The Audit Committee approved the dismissal and engagement of EisnerAmper LLP as new auditor for FY 2023.","EY's reports for 2022 and 2021 contained no adverse opinion or qualification; no disagreements or reportable events existed.","No consultations with EisnerAmper occurred prior to engagement on any accounting matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321504,"accession_number":"0001104659-23-039155","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics reports FY2022 net loss of $112.7M; cash $28.8M, runway into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $28.8M at Dec 31, 2022, down from $53.1M; with $5.5M public offering, runway into Q3 2024.","Q4 2022 net loss $2.4M ($0.92/share) vs $7.8M ($7.20/share) in Q4 2021; operating loss $2.7M vs $7.8M.","Full year 2022 net loss $112.7M ($67.99/share) including $76M acquired IPR&D, vs $37.1M in 2021.","R&D expenses fell to $0.5M in Q4 2022 from $4.5M as legacy trials wrapped; only one active trial vs six.","ATRN-119 Phase 1/2a enrolling; ATRN-1051 IND filing expected by end of 2023; AACR abstract selected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321503,"accession_number":"0001104659-23-031393","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aprea Therapeutics discloses $1.5M SVB deposits, $28.9M in SVB-purchased money market fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash deposits of approximately $1.5M held at Silicon Valley Bank (SVB) after FDIC takeover.","Additional $28.9M in a money market mutual fund purchased through SVB, managed by a third party.","Company expects full access to the money market fund but timing and process remain unclear as of March 13.","Total potential exposure of $30.4M represents a material portion of the company's cash position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321502,"accession_number":"0001104659-23-027442","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on Sept 12, 2022 for bid price below $1.00.","Regained compliance on March 1, 2023 after 10 consecutive trading days above $1.00 (Feb 14-28).","CEO Oren Gilad cited recent financing and progress on clinical asset ATRN-119 and pre-clinical ATRN-W1051."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321501,"accession_number":"0001104659-23-025392","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics prices $5.5M public offering of 1.05M shares at $5.25/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5.5M from 1,050,000 shares at $5.25/share; net proceeds ~$4.8M after discounts and expenses.","Underwriters granted 30-day option to purchase up to 157,500 additional shares.","Proceeds to fund clinical asset ATRN-119, pre-clinical ATRN-W1051, and general corporate purposes.","Offering expected to close Feb 27, 2023; Maxim Group LLC sole book-runner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321500,"accession_number":"0001104659-23-019906","cik":1781983,"company_name":"Aprea Therapeutics, Inc.","ticker":"APRE","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aprea Therapeutics completes 1-for-20 reverse stock split; Nasdaq halt through Feb 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split 1-for-20 effective 5:00 p.m. ET on Feb 10, 2023.","Nasdaq halted trading in APRE at 7:50 p.m. Feb 10 pending material news related to split.","Halt is administrative; trading expected to resume at 9:45 a.m. on Feb 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":11385962.60277717,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-14T23:59:59+00:00|321500"}